EGFR and MUC1 as dual-TAA drug targets for lung cancer and colorectal cancer
Single-cell RNA, bulk RNA and IHC data demonstrated the high expression levels and co-expression patterns of EGFR and MUC1 in tumors but not normal tissues. Therefore, it is a promising TAA combination for therapeutic targeting which could enhance on-tumor efficacy while reducing off-tumor toxicity.
Authors
- Yilu Zhou (ORCID: https://orcid.org/0000-0002-4090-099X)
- Qumiao Xu
- Feilin Cao (ORCID: https://orcid.org/0009-0002-5083-1462)
- Runfeng Sun (ORCID: https://orcid.org/0009-0009-7908-0106)
- Yifei Yang (ORCID: https://orcid.org/0000-0001-9817-484X)
- Jinfeng Ma (ORCID: https://orcid.org/0000-0002-1479-9605)
- Ningning Yao
- Cheng Liao (ORCID: https://orcid.org/0000-0003-2974-2158)
- Long Zhang
- Meilin Liu (ORCID: https://orcid.org/0000-0001-7005-9292)
- Ye Wei (ORCID: https://orcid.org/0000-0003-1994-5664)
- Lin Chen (ORCID: https://orcid.org/0000-0002-6453-7996)
- Haizhen Wang (ORCID: https://orcid.org/0000-0003-3477-8673)
- Qianqian Yu
- Ruifang Sun (ORCID: https://orcid.org/0000-0001-8502-5271)
- Sijia Tian (ORCID: https://orcid.org/0000-0001-7764-2317)
- Huilin Cui (ORCID: https://orcid.org/0000-0002-1403-3562)
- Yongsheng Meng (ORCID: https://orcid.org/0000-0001-8063-7682)
Institutions
- Shanxi Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-11-27
- DOI
- https://doi.org/10.3389/fonc.2024.1433033
- Citations
- 4
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.68